APUS stock

Apimeds Pharmaceuticals US, Inc. (APUS) financials · $2.4M cap

Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT

Apimeds Pharmaceuticals US, Inc. (APUS) $2.4M cap.

Cached annual income statement
LineFY2025FY2024
Operating Income-$11.9M-$1.28M
Net Income-$6.00M-$1.39M
EPS (Diluted)-$0.55-$0.18
Cached annual balance sheet
LineFY2025FY2024
Total Assets$164.2M$13.1K
Current Assets$14.0M$13.1K
Cash & Equivalents$1.64M$3.46K
PP&E$51.6KN/A
Total Liabilities$10.8M$1.37M
Current Liabilities$10.7M$1.02M
Shareholders' Equity$153.3M-$1.36M
Retained Earnings-$10.4M-$4.39M
Cached annual cash flow
LineFY2025FY2024
Operating Cash Flow-$8.93M-$733.5K
CapEx$57.3KN/A
Investing Cash Flow-$10.1MN/A
Financing Cash Flow$20.6M$326.5K
Free Cash Flow-$8.98MN/A
These statements as JSON? API free 100/day

FAQ

What is APUS P/E and revenue?

Apimeds Pharmaceuticals US, Inc. (APUS) $2.4M cap.

What is APUS revenue?

APUS income-statement cache has no revenue figure yet.

Is APUS profitable?

Apimeds Pharmaceuticals US, Inc. last cached net income is -$6.00M (FY2025).

What are APUS total assets?

Apimeds Pharmaceuticals US, Inc. last cached total assets are $164.2M (FY2025).

What is APUS free cash flow?

Apimeds Pharmaceuticals US, Inc. last cached free cash flow is -$8.98M (FY2025).

Not investment advice. Cached statements, not a live tape.